[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619355":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":19,"responsibleParty":35,"collaborators":37,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":19,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":69,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":19},{"fullName":5,"class":6},"AB Biotics, SA","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study Arm","OTHER","Open Label Active Product",[13],"Other: Active cream",[15],{"type":10,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Active cream","Active facial cream with postbiotics.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Ester Moreno Artero, PhD","Dr. Goya Análisis","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Jordi Espadaler, PhD","CONTACT","+34 659055442","espadaler@ab-biotics.com",{"name":32,"role":28,"phone":33,"phoneExt":19,"email":34},"Nuria Gispets, MSc","+34 607026612","gispets@ab-biotics.com",{"type":36,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[38],{"name":39,"class":6},"Dr. Goya Análisis, SL.","100619355","clinical-trial-to-assess-the-efficacy-and-safety-of-a-cosmetic-product-in-individuals-showing-signs-of-cutaneous-aging-100619355",false,"NCT07343544","Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.","Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.","SkinMeter","Inclusion Criteria:\n\n* Female participants.\n* Age between 35 and 60 years.\n* All skin types (combination, oily, dry, and\u002For normal).\n* Skin condition: 50% sensitive skin and 50% normal skin.\n* Visible signs of facial skin aging (mild\u002Fmoderate wrinkles and\u002For pigmentation spots).\n* Willingness to participate voluntarily and provide written informed consent.\n* Ability to understand the study objectives and procedures.\n* Good general health (physical and mental).\n* Availability to attend all scheduled visits at the research center.\n* Discontinuation of anti-aging products on the experimental area (face) at least 7 days prior to study start.\n* Commitment not to change facial hygiene routines during the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of allergy to cosmetic products and\u002For dietary supplements.\n* Known allergy or hypersensitivity to any component of the product.\n* History or current diagnosis of cancer.\n* Active skin diseases or infections in the experimental area.\n* Recent or planned surgical or aesthetic interventions in the experimental area Medical-aesthetic treatments on the face within the last 6 months (e.g., botulinum toxin, hyaluronic acid, laser, radiofrequency, HIFU, deep chemical peels, microneedling with actives).\n* Relevant dermatological conditions in the experimental area (eczema, psoriasis, allergic\u002Fcontact dermatitis, etc.).\n* Use of topical or systemic medications affecting the skin (retinoids, antibiotics, corticosteroids) within the last 3 months.\n* Current or planned use of supplements that may affect skin health (collagen, antioxidant vitamins A\u002FC\u002FE, zinc, omega-3, oral probiotics\u002Fprebiotics).\n* Systemic diseases such as autoimmune disorders (rheumatoid arthritis, lupus, multiple sclerosis), chronic viral infections (HIV, hepatitis B\u002FC), or severe metabolic diseases.\n* Use of any product other than the study product on the experimental area during the study.\n* Planned significant changes in health habits during the study (diet, physical activity, structured exercise programs).\n* Recent or planned changes in hormonal contraceptives.\n* Sun or UVA exposure during the study.\n* Participation in another clinical study involving the same experimental area\n* Application of any product on the experimental area on the day of study initiation.\n* Any medical condition, at the investigator's discretion, that may interfere with protocol adherence or participant safety.",true,"FEMALE","35 Years","60 Years",{"count":53,"type":54},45,"ESTIMATED","INTERVENTIONAL",[57],"NA","This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging.\n\nThe study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®).\n\nSafety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.",[60,61,62,63,64],"Skin","Skin Ageing","Fine Lines","Face Aging\u002FPhoto Aging of Moderate Grade","Face Skin Photoaging",[66,67,60,68],"Face Skin","Postbiotics","Skin ageing","NOT_YET_RECRUITING","2026-01-08",{"date":72,"type":73},"2026-01-15","ACTUAL",{"date":75,"type":54},"2026-02",{"date":77,"type":54},"2026-05",{"name":5,"class":6}]